After successful primary percutaneous coronary intervention in ST-segment elevation myocardial infarction, adequate myocardial reperfusion is not achieved in up to 50% of patients. This phenomenon of no-reflow is associated with a poor in-hospital and long-term prognosis. Four main factors are thought to contribute to the occurrence of no-reflow: ischaemic injury; reperfusion injury; distal embolization; susceptibility of the microcirculation to injury. This review evaluates the literature, and in particular the clinical trials, concerned with pharmacological and physical methods for prevention and treatment of no-reflow. A number of drugs may improve no-reflow experimentally and clinically, but some have not yet been associated with conclusive improvements in clinical outcome. The complex interacting factors in no-reflow make it unlikely that any single agent will be effective for all patients. Confirmed methods known to be beneficial in the prevention of no-reflow (such as aspirin therapy, chronic statin therapy, blood glucose control, thrombus aspiration in patients with a high thrombus burden and ischaemic preconditioning) should be offered to patients as often as possible, to prevent and treat no-reflow.
Introduction
The main goals of primary percutaneous coronary intervention (PPCI) in ST-segment elevation myocardial infarction (STEMI) are to establish the patency of the infarctrelated artery and to achieve microvascular reperfusion as soon as possible, thus limiting the development of necrotic myocardium. 1 However, even after successful PPCI for STEMI, adequate myocardial reperfusion is not achieved in 5-50% of patients, depending on how it is measured. 2 This phenomenon of inadequate myocardial perfusion of a given coronary segment without angiographic evidence of mechanical vessel obstruction is termed no-reflow, and is associated with poor in-hospital and longterm prognosis. 3 Four interacting factors are thought to contribute to the occurrence of no-reflow: ischaemic injury; reperfusion injury; distal embolization; susceptibility of the microcirculation to injury. 2 Ischaemiareperfusion injury is central to the pathophysiology of no-reflow and is associated with a profound disturbance of the vasoregulatory pathways. 4 The present review evaluates the literature -and in particular the published clinical trials -that describe pharmacological and physical methods for the prevention and treatment of no-reflow after PPCI in patients with STEMI.
Pharmacological prevention and treatment of ischaemic injury Protection of endothelial function
Ischaemic injury affects endothelial cells, which exhibit intracellular acidosis and overload of Na þ and Ca 2þ ions, leading to cell swelling that obliterates the vessel lumen. Carvedilol, fosinopril and valsartan have been shown to protect endothelial function and to have beneficial effects on coronary no-reflow and infarct size in animal models of coronary ligation and reperfusion. [5] [6] [7] However, there are no published data on the effects of these drugs on indexes of no-reflow in humans.
Pharmacological ischaemic preconditioning
Ischaemic preconditioning (IPC) has been reported to reduce infarct size by half after coronary ligation and reperfusion. 8 Drugs such as nitrates have been shown to produce a preconditioning effect in animals and humans, 9, 10 while chronic nitrate therapy was associated with reduced release of cardiac necrosis markers, suggesting that nitrates may pharmacologically precondition the heart towards ischaemic episodes. 11
Pharmacological prevention and treatment of reperfusion injury Adenosine
Reperfusion injury is a complex process that involves interplay between neutrophils and platelets, which may mechanically plug the microcirculation and release oxygen radicals and proteases, causing endothelial and interstitial damage. 4 Adenosine, an endogenous nucleoside, antagonizes many of the biochemical and physiological mechanisms implicated in ischaemia-reperfusion injury. For example, adenosine has been shown to inhibit neutrophil function and, in particular, neutrophil-mediated injury to endothelial cells. 12 It has been demonstrated in experimental models that exogenous or endogenous adenosine can inhibit neutrophil adhesion and injury to myocytes by an A2 receptor-mediated mechanism in cells activated with tumour necrosis factor-a. 13 The exact mechanisms of the cardioprotective effects of adenosine are not fully understood, although anti-inflammatory properties, inhibition of neutrophil and platelet activation and prevention of endothelial damage all seem to play principal roles. 14 In a small randomized trial, intracoronary administration of 4 mg adenosine before complete vessel re-opening resulted in a lower rate of no-reflow when compared with controls. 15 A study by Claeys et al. 16 showed that adjunctive therapy with an intracoronary infusion of adenosine during PPCI reduced the occurrence of severe myocardial reperfusion injury and was associated with less infarct expansion, compared with controls. Grygier et al. 17 reported a new, simple protocol for intracoronary adenosine administration during primary angioplasty. Patients received intracoronary adenosine two times: immediately after the guidewire had crossed the lesion in the infarct-related artery; again, after the first balloon inflation. They found that intracoronary adenosine administration improved the angiographic and electrocardiographic results in patients with STEMI undergoing PPCI. Conversely, a large trial of adenosine after thrombus aspiration did not result in better ST-segment resolution when compared with placebo. 18 Stoel et al. 19 reported that intracoronary administration of adenosine was associated with early improvement in electrocardiographically derived indexes of no-reflow, compared with placebo, in 51 patients with STEMI undergoing PPCI. However, the occurrence of optimal STsegment resolution (>70%) was similar in the adenosine-and placebo-treated coronary care unit patients, suggesting that adenosine treatment accelerated ST-segment resolution but did not decrease the final rate of persistent ST-segment elevation. 19 Intravenous (i.v.) adenosine has been tested in two large randomized trials (AMISTAD 20 and AMISTAD-II 21 ). In these trials, drug therapy started before PPCI and continued for 3 h. In both studies, ST-segment resolution was improved with adenosine; in addition, infarct size was reduced with a high-dose infusion (70 mg/kg per min). However, in-hospital and 6-month clinical outcomes were similar in the adenosine groups to those observed in the placebo group. 21, 22 Post hoc analysis of the AMISTAD-II trial found that if patients received reperfusion within 3.17 h, adenosine significantly reduced 1-and 6-month mortality rates and the occurrence of the composite clinical endpoint of death, in-hospital congestive heart failure or rehospitalization for congestive heart failure at 6 months, compared with placebo. 22 However, patients reperfused >3.17 h did not benefit from adenosine administration. 22 In addition, the ADMIRE study 23which was undertaken in 311 patients undergoing primary percutaneous transluminal coronary angioplasty after acute STEMI -reported that AMP579 (a mixed adenosine agonist with both A1 and A2 effects), administered via continuous i.v. infusion over a 6-h period, did not reduce infarct size compared with placebo.
Nicorandil
Nicorandil is a hybrid between a mitochondrial K þ channel opener and NO that can dilate coronary resistance vessels, reduce Ca 2þ overload of myocytes and attenuate neutrophil activation. 24 The opening of ATP-sensitive K þ channels may constitute one response of the cardiac myocyte to potentially injurious ischaemic stress. 25 Nicorandil opens cardiac ATP-sensitive K þ channels and so may afford cardioprotection by reducing the functional and biochemical damage produced by ischaemia. A single i.v. administration of nicorandil before PPCI was shown to improve angiographic indexes of no-reflow and clinical outcome. 26 In addition, i.v. infusion of nicorandil for 24 h after PPCI resulted in better angiographic, functional and clinical outcomes when compared with placebo. 27, 28 However, another study in which 276 patients were randomly assigned to i.v. nicorandil or placebo showed no difference in infarct size or left ventricular ejection fraction between the study group and controls. 29 
Verapamil
In a small randomized study by Taniyama et al., 30 intracoronary verapamil, a Ca 2þ antagonist, was associated with better microvascular function (assessed by myocardial contrast echocardiography) when compared with placebo in 40 patients with a first STEMI. An additional small trial reported some improvement in thrombolysis in myocardial infarction (TIMI) grade flow after the use of intracoronary verapamil to reverse no-reflow during PPCI. 31 
Nitroprusside and atrial natriuretic peptide
Nitroprusside and atrial natriuretic peptide (ANP) could increase intracellular cyclic guanosine monophosphate, which may result in effective antiplatelet action in ischaemia-reperfusion injury and decrease the susceptibility to ventricular fibrillation that is normally encountered in hearts reperfused after sustained ischaemia. 32 Intracoronary nitroprusside was used for the treatment of no-reflow after PPCI in two small studies, and was associated with an improvement in final TIMI grade flow. 33, 34 However, in a randomized trial for the prevention of no-reflow after PPCI in 98 patients presenting with STEMI, in which intracoronary nitroprusside was given beyond the occlusion prior to balloon dilatation, angiographic parameters (namely, corrected TIMI frame count and myocardial blush grade) and ST-segment resolution were similar in the nitroprusside and control groups. 35 In the J-Wind trial, ANP reduced the infarct size, improved the ejection fraction and reduced reperfusion injury when administered at the time of PPCI; however, the rate of final TIMI grade 3 flow was similar in the ANP group and controls. 29 Other drugs A number of other drugs have shown potential beneficial effects in the prevention and treatment of no-reflow. Cyclosporin-A may prevent the opening of mitochondrial permeability transition pores, which have a central role in reperfusion injury by leading to mitochondrial swelling and cell death. 36 A small study showed that cyclosporin-A could reduce infarct size when given at the time of reperfusion during PPCI; however, final TIMI grade flow was similar in the cyclosporin-A and control groups. 37 FX06, a peptide derived from human fibrin, may improve the necrotic core zone; however, it failed to reduce infarct size (assessed by cardiac magnetic resonance imaging), compared with placebo. 38 In the ENLEAT trial, Tongxinluo (a traditional Chinese medicine) significantly reduced myocardial no-reflow and the infarction area after PPCI for STEMI, compared with placebo. 39 
Prevention and treatment of ischaemia-reperfusion injury
Remote conditioning stimuli have complex effects on neutrophil adhesion function. 40 Cycles of intermittent limb ischaemia provide an acceptable method for inducing cardioprotection, and early proof-of-concept studies have confirmed the effectiveness of remote IPC in cardiac surgery and coronary angioplasty, as evidenced by reduced markers of cardiac injury. 41 A study by Posa et al. 42 in pigs showed that IPC (applied using two cycles of 5 min occlusion and 5 min reperfusion of the left anterior descending coronary artery before induction of myocardial infarction) attenuated release of myeloperoxidase and platelet activation after ischaemia-reperfusion, thus improving perfusion. In a randomized clinical study, Bøtker et al. 43 found that remote preconditioning by intermittent arm ischaemia (using four cycles of 5 min inflation and 5 min deflation of a blood-pressure cuff) increased the myocardial salvage index, as measured by myocardial perfusion imaging. A metaanalysis including 244 patients treated by PPCI suggested that preconditioning resulted in lower mean peak creatine kinase release, and improved left ventricular ejection fraction and myocardial reperfusion, compared with controls. 44 Interestingly, Rentoukas et al. 45 showed that the beneficial effect of remote IPC on ST-segment resolution in patients treated by PPCI was increased by the concomitant administration of morphine. Remote preconditioning is unique in that it can be applied during myocardial ischaemia, prior to reperfusion. 42 Garcia et al. 46 demonstrated that a simple postconditioning protocol (performed immediately on crossing the lesion with the angioplasty guidewire, and consisting of four cycles of 30 s of occlusion followed by 30 s of reperfusion), applied at the onset of mechanical reperfusion, resulted in a reduction in infarct size, better epicardial and myocardial flow and improved left ventricular function. In addition, the beneficial effects of postconditioning on cardiac function were shown to persist >3 years. 46 
Pharmacological prevention and treatment of distal embolization
Distal embolization from the culprit plaque and thrombus can cause sustained ischaemia and necrosis of embolized regions. The risk of distal embolization is related to the thrombus burden. 47 
Aspirin
Niccoli et al. 48 demonstrated that STEMI patients on previous aspirin therapy had a lower thrombotic burden at angiography compared with those without previous aspirin therapy.
Glycoprotein IIb/IIIa inhibitors
Glycoprotein IIb/IIIa inhibitors can be used to reduce the thrombus burden. 49 Abciximab binds to the vitronectin receptor on endothelial, smooth muscle and inflammatory cells, including neutrophils, and to an activated conformation of the aMb2 receptor on leucocytes, thus reducing neutrophil adhesion to the endothelium. 50 Abciximab treatment (which is administered intravenously) has been found to improve myocardial perfusion when started in the catheterization laboratory prior to balloon inflation and infused for 12 h thereafter, as evidenced by a higher rate of ST-segment resolution >50% at 60 min post-PPCI in abciximab-treated patients. 51 In addition, abciximab has been confirmed to have a beneficial and persistent impact on hard clinical endpoints (death or re-infarction during 3 years' follow-up) in patients undergoing primary stenting for STEMI. 52 Intracoronary abciximab has been shown to be superior to i.v. abciximab in patients with STEMI treated by PPCI. 53 Interestingly, in a medium-scale randomized clinical trial involving 534 patients with STEMI undergoing PPCI with thrombus aspiration, intracoronary administration of abciximab compared with i.v. administration did not improve myocardial reperfusion when assessed by ST-segment resolution. 54 However, intracoronary administration of abciximab was associated with improved myocardial reperfusion, as assessed by myocardial blush grade, and with a smaller enzymatic infarct size, compared with i.v. administration of this agent. 54 Prati et al. 55 demonstrated that pre-catheterization laboratory administration of abciximab, i.v., alone (and especially in combination with half-dose reteplase (10MU), administered via i.v. infusion) resulted in higher rates of infarct-related artery patency at baseline coronary angiography compared with no pretreatment. However, post-procedural angiographic and microcirculatory variables were unaffected by facilitation therapy. In contrast, in the BRAVE-3 randomized trial, 56 administration of abciximab (i.v.) did not improve overall clinical outcomes at 1 year after PPCI, in patients with STEMI receiving 600 mg clopidogrel, orally.
Eptifibatide, which is another glycoprotein IIb/IIIa inhibitor, has also been shown to improve the microcirculation, when administered by the intracoronary route. 57 
Prevention and treatment of distal embolization
Physical methods used to reduce the thrombus or plaque burden include aspiration of embolic materials with catheter-based devices or the trapping of embolic materials with distal protection devices. In a large, randomized, controlled trial, Svilaas et al. 58 showed that thrombus aspiration during PPCI, in patients with STEMI, resulted in significantly better ST-segment resolution and reduced the risk of poor reperfusion (manifesting as a myocardial blush grade of 0 or 1) from 26.3% to 17.1%, compared with conventional PPCI via a reduction in distal embolization. A number of metaanalyses of previous studies have reached similar conclusions. 59-61 However, it is not clear whether these benefits also lead to smaller infarcts or better clinical outcomes. [62] [63] [64] Distal embolic protection failed to show improved microvascular flow, greater reperfusion success, reduced infarct size or enhanced event-free survival. 65, 66 Prevention and treatment of susceptibility of microcirculation to injury Individual susceptibility of the microcirculation to ischaemia-reperfusion injury is determined by genetic factors, 67 although acquired risk factors (such as diabetes 68 and hypercholesterolaemia 69 ) may modulate its occurrence. The presence of chronic total occlusions in a noninfarct-related coronary artery in patients with STEMI has been shown to be associated with impaired reperfusion markers and a worse long-term outcome. 70 In 44 patients with STEMI, Ohshima et al. 71 found that plaque composed of fibrofatty-rich elements, with a necrotic core or dense calcium on virtual histology intravascular ultrasound, was closely related to angiographic no-reflow after PPCI. Iwakura et al. 72 demonstrated that chronic statin therapy in patients with or without hypercholesterolaemia was associated with a lower prevalence of no-reflow and better functional recovery. In addition, the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction study 73 reported that a periprocedural reduction in blood glucose was associated with a reduction in infarct size.
Conclusions
Identification of the main factors leading to no-reflow in PPCI for STEMI is key to defining specific therapeutic strategies for reperfusion. A number of drugs may improve no-reflow experimentally and clinically; those described above are also presented in Table 1 . However, some of these drugs have not yet been shown to be associated with conclusive improvements in clinical outcome. The lack of beneficial effects for drugs used after no-reflow has occurred may be due to progressive impairment of the microcirculation. The complex interacting factors in no-reflow make it unlikely that any single agent will be effective for all patients. The use of appropriate doses, administration routes and drug combinations may be important in improving the effects of these drugs.
Some confirmed methods are known to be beneficial in the prevention of no-reflow, such as aspirin therapy, chronic statin therapy, blood glucose control, thrombus aspiration (in patients with a high thrombus burden) and IPC. Such therapies should be offered to patients as often as possible, to prevent and treat no-reflow.
At present, no-reflow is mainly assessed using TIMI flow evaluation. However, the development of accurate diagnostic techniques that can assess the success or failure of cardiac tissue will greatly benefit the further evolution of preventative and therapeutic methods in no-reflow.
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